GlassScriptPhysician profile
Jason Cohn
NPI 1568855625
$2,012.20
in general payments reported to CMS, 2019-2025
14 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.40 · 2021: $413 · 2022: $447 · 2024: $593 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070 · Education: $59.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.34 |
| Education | $59.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $344.43 | 2021-2022 | |
| Optinose US, INC. | $328.08 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $302.09 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $291.87 | 2024-2025 | Nucala |
| Aerin Medical INC. | $278.62 | 2022-2025 | |
| Intersect Ent, INC. | $265.63 | 2020-2022 | |
| Innovation Technologies INC | $33.41 | 2025 | Irrisept |
| Kerecis Limited | $28.38 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Phathom Pharmaceuticals, INC. | $28.24 | 2024 | Voquezna |
| Supernus Pharmaceuticals, INC. | $27.11 | 2022 | |
| Integra Lifesciences Corporation | $26.09 | 2024 | Inspira Air, Acclarent Aera, Trudi Probe |
| Mimedx Group, INC. | $24.05 | 2024 | |
| Phadia US INC. | $19.22 | 2025 | Immunocap |
| Cumberland Pharmaceuticals, INC. | $14.98 | 2024 | Caldolor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Cohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.